Sedation and analgesia from prolonged pain and stress during mechanical ventilation in preterm infants: is dexmedetomidine an alternative to current practice?

Shalini Ojha, Janine Abramson, Jon Dorling, Shalini Ojha, Janine Abramson, Jon Dorling

Abstract

Mechanical ventilation is an uncomfortable and potentially painful intervention. Opioids, such as morphine and fentanyl, are used for analgesia and sedation but there is uncertainty whether they reduce pain in mechanically ventilated infants. Moreover, there may be short-term and long-term adverse consequences such as respiratory depression leading to prolonged mechanical ventilation and detrimental long-term neurodevelopmental effects. Despite this, opioids are widely used, possibly due to a lack of alternatives.Dexmedetomidine, a highly selective alpha-2-adrenergic agonist with analgesic and sedative effects, currently approved for adults, has come into use in newborn infants. It provides analgesia and simulates natural sleep with maintenance of spontaneous breathing and upper airway tone. Although data on pharmacokinetics-pharmacodynamics in preterm infants are scant, observational studies report that using dexmedetomidine in conjunction with opioids/benzodiazepines or on its own can reduce the cumulative exposure to opioids/benzodiazepines. As it does not cause respiratory depression, dexmedetomidine could enable quicker weaning and extubation. Dexmedetomidine has also been suggested as an adjunct to therapeutic hypothermia in hypoxic ischaemic encephalopathy and others have used it during painful procedures and surgery. Dexmedetomidine infusion can cause bradycardia and hypotension although most report clinically insignificant effects.The increasing number of publications of observational studies and clinical use demonstrates that dexmedetomidine is being used in newborn infants but data on safety and efficacy are scant and not of high quality. Importantly, there are no data on long-term neurodevelopmental impact on preterm or term-born infants. The acceptance of dexmedetomidine in routine clinical practice must be preceded by clinical evidence. We need adequately powered and well-designed randomised controlled trials investigating whether dexmedetomidine alone or with opioids/benzodiazepines in infants on mechanical ventilation reduces the need for opioids/benzodiazepine and improves neurodevelopment at 24 months and later as compared with the use of opioids/benzodiazepines alone.

Keywords: neonatology; pain; pharmacology; therapeutics.

Conflict of interest statement

Competing interests: SO has received funds from the National Institute of Health Research, UK and the Medical Research Council, UK for other research. JD has received funds from the National Institute of Health Research, UK, Canadian Institute for Health Research, Canada, Nova Scotia Research, Canada and Action Medical Research, UK for other research

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

References

    1. Sand L, Szatkowski L, Kwok T'ng Chang, et al. . Observational cohort study of changing trends in non-invasive ventilation in very preterm infants and associations with clinical outcomes. Arch Dis Child Fetal Neonatal Ed 2022;107:150–5. 10.1136/archdischild-2021-322390
    1. Bellù R, Romantsik O, Nava C, et al. . Opioids for newborn infants receiving mechanical ventilation. Cochrane Database Syst Rev 2021;3:CD013732. 10.1002/14651858.CD013732.pub2
    1. COMMITTEE ON FETUS AND NEWBORN and SECTION ON ANESTHESIOLOGY AND PAIN MEDICINE . Prevention and management of procedural pain in the neonate: an update. Pediatrics 2016;137:e20154271. 10.1542/peds.2015-4271
    1. Anand KJ. Clinical importance of pain and stress in preterm neonates. Biol Neonate 1998;73:1–9. 10.1159/000013953
    1. Anand KJ, Sippell WG, Aynsley-Green A. Randomised trial of fentanyl anaesthesia in preterm babies undergoing surgery: effects on the stress response. Lancet 1987;1:243–8. 10.1016/s0140-6736(87)90065-1
    1. McPherson C, Miller SP, El-Dib M, et al. . The influence of pain, agitation, and their management on the immature brain. Pediatr Res 2020;88:168–75. 10.1038/s41390-019-0744-6
    1. Carbajal R, Eriksson M, Courtois E, et al. . Sedation and analgesia practices in neonatal intensive care units (EUROPAIN): results from a prospective cohort study. Lancet Respir Med 2015;3:796–812. 10.1016/S2213-2600(15)00331-8
    1. Zimmerman KO, Smith PB, Benjamin DK, et al. . Sedation, analgesia, and paralysis during mechanical ventilation of premature infants. J Pediatr 2017;180:99–104. 10.1016/j.jpeds.2016.07.001
    1. Ancora G, Lago P, Garetti E, et al. . Evidence-Based clinical guidelines on analgesia and sedation in newborn infants undergoing assisted ventilation and endotracheal intubation. Acta Paediatr 2019;108:208–17. 10.1111/apa.14606
    1. Ancora G, Lago P, Garetti E, et al. . Efficacy and safety of continuous infusion of fentanyl for pain control in preterm newborns on mechanical ventilation. J Pediatr 2013;163:645–51. 10.1016/j.jpeds.2013.02.039
    1. MacGregor R, Evans D, Sugden D, et al. . Outcome at 5-6 years of prematurely born children who received morphine as neonates. Arch Dis Child Fetal Neonatal Ed 1998;79:F40–3. 10.1136/fn.79.1.F40
    1. Puia-Dumitrescu M, Comstock BA, Li S, et al. . Assessment of 2-year neurodevelopmental outcomes in extremely preterm infants receiving opioids and benzodiazepines. JAMA Netw Open 2021;4:e2115998. 10.1001/jamanetworkopen.2021.15998
    1. Al-Turkait A, Szatkowski L, Choonara I, et al. . Drug utilisation in neonatal units in England and Wales: a national cohort study. Eur J Clin Pharmacol 2022;78:669–77. 10.1007/s00228-021-03267-x
    1. Gertler R, Brown HC, Mitchell DH, et al. . Dexmedetomidine: a novel sedative-analgesic agent. Proc 2001;14:13–21. 10.1080/08998280.2001.11927725
    1. European Medicines Agency . Dexmedetomidine accord, 2022. Available: [Accessed 11 Feb 2022].
    1. O'Mara K, Gal P, Ransommd JL, et al. . Successful use of dexmedetomidine for sedation in a 24-week gestational age neonate. Ann Pharmacother 2009;43:1707–13. 10.1345/aph.1M245
    1. Mahmoud M, Barbi E, Mason KP. Dexmedetomidine: What’s New for Pediatrics? A Narrative Review. J Clin Med 2020;9:2724. 10.3390/jcm9092724
    1. Schoeler M, Loetscher PD, Rossaint R, et al. . Dexmedetomidine is neuroprotective in an in vitro model for traumatic brain injury. BMC Neurol 2012;12:20. 10.1186/1471-2377-12-20
    1. Cosnahan AS, Angert RM, Jano E, et al. . Dexmedetomidine versus intermittent morphine for sedation of neonates with encephalopathy undergoing therapeutic hypothermia. J Perinatol 2021;41:2284–91. 10.1038/s41372-021-00998-8
    1. Ren X, Ma H, Zuo Z. Dexmedetomidine postconditioning reduces brain injury after brain hypoxia-ischemia in neonatal rats. J Neuroimmune Pharmacol 2016;11:238–47. 10.1007/s11481-016-9658-9
    1. Ezzati M, Kawano G, Rocha-Ferreira E, et al. . Dexmedetomidine combined with therapeutic hypothermia is associated with cardiovascular instability and neurotoxicity in a piglet model of perinatal asphyxia. Dev Neurosci 2017;39:156–70. 10.1159/000458438
    1. Pancaro C, Segal BS, Sikes RW, et al. . Dexmedetomidine and ketamine show distinct patterns of cell degeneration and apoptosis in the developing rat neonatal brain. J Matern Fetal Neonatal Med 2016;29:3827–33. 10.3109/14767058.2016.1148132
    1. Cortes-Ledesma C, Arruza L, Sainz-Villamayor A, et al. . Dexmedetomidine affects cerebral activity in preterm infants. Arch Dis Child Fetal Neonatal Ed 2022. 10.1136/archdischild-2021-323411. [Epub ahead of print: 14 Mar 2022].
    1. Duerden EG, Guo T, Dodbiba L, et al. . Midazolam dose correlates with abnormal hippocampal growth and neurodevelopmental outcome in preterm infants. Ann Neurol 2016;79:548–59. 10.1002/ana.24601
    1. van Dijkman SC, De Cock PAJG, Smets K, et al. . Dose rationale and pharmacokinetics of dexmedetomidine in mechanically ventilated new-borns: impact of design optimisation. Eur J Clin Pharmacol 2019;75:1393–404. 10.1007/s00228-019-02708-y
    1. Estkowski LM, Morris JL, Sinclair EA. Characterization of dexmedetomidine dosing and safety in neonates and infants. J Pediatr Pharmacol Ther 2015;20:112–8. 10.5863/1551-6776-20.2.112
    1. Potts AL, Anderson BJ, Warman GR, et al. . Dexmedetomidine pharmacokinetics in pediatric intensive care--a pooled analysis. Paediatr Anaesth 2009;19:1119–29. 10.1111/j.1460-9592.2009.03133.x
    1. O'Mara K, Gal P, Wimmer J, et al. . Dexmedetomidine versus standard therapy with fentanyl for sedation in mechanically ventilated premature neonates. J Pediatr Pharmacol Ther 2012;17:252–62. 10.5863/1551-6776-17.3.252
    1. Chrysostomou C, Schulman SR, Herrera Castellanos M, et al. . A phase II/III, multicenter, safety, efficacy, and pharmacokinetic study of dexmedetomidine in preterm and term neonates. J Pediatr 2014;164:276–82. 10.1016/j.jpeds.2013.10.002
    1. McAdams RM, Pak D, Lalovic B, et al. . Dexmedetomidine pharmacokinetics in neonates with hypoxic-ischemic encephalopathy receiving hypothermia. Anesthesiol Res Pract 2020;2020:1–15. 10.1155/2020/2582965
    1. Finkel JC, Quezado ZMN. Hypothermia-Induced bradycardia in a neonate receiving dexmedetomidine. J Clin Anesth 2007;19:290–2. 10.1016/j.jclinane.2006.08.011
    1. Sellas MN, Kyllonen KC, Lepak MR, et al. . Dexmedetomidine for the management of postoperative pain and sedation in newborns. J Pediatr Pharmacol Ther 2019;24:227–33. 10.5863/1551-6776-24.3.227
    1. Dersch-Mills DA, Banasch HL, Yusuf K, et al. . Dexmedetomidine use in a tertiary care NICU: a descriptive study. Ann Pharmacother 2019;53:464–70. 10.1177/1060028018812089
    1. Elliott M, Burnsed J, Heinan K, et al. . Effect of dexmedetomidine on heart rate in neonates with hypoxic ischemic encephalopathy undergoing therapeutic hypothermia. J Neonatal Perinatal Med 2022;15:47–54. 10.3233/NPM-210737
    1. O'Mara K, Weiss MD. Dexmedetomidine for sedation of neonates with HIE undergoing therapeutic hypothermia: a single-center experience. AJP Rep 2018;8:e168–73. 10.1055/s-0038-1669938
    1. Inserra E, Colella U, Caredda E, et al. . Safety and effectiveness of intranasal dexmedetomidine together with midazolam for sedation in neonatal MRI. Paediatr Anaesth 2022;32:79–81. 10.1111/pan.14307
    1. Bua J, Massaro M, Cossovel F, et al. . Intranasal dexmedetomidine, as midazolam-sparing drug, for MRI in preterm neonates. Paediatr Anaesth 2018;28:747–8. 10.1111/pan.13454
    1. Stark A, Smith PB, Hornik CP, et al. . Medication Use in the Neonatal Intensive Care Unit and Changes from 2010 to 2018. J Pediatr 2022;240:66–71. 10.1016/j.jpeds.2021.08.075
    1. Morton SU, Labrecque M, Moline M, et al. . Reducing benzodiazepine exposure by Instituting a guideline for dexmedetomidine usage in the NICU. Pediatrics 2021;148:e2020041566. 10.1542/peds.2020-041566
    1. UpToDate . Lexicomp-UpToDate dexmedetomidine: pediatric drug information. Available: [Accessed 29 Mar 2022].
    1. BNF FOR CHILDREN (BNFC) . 2020-2021. s.l. PHARMACEUTICAL PRESS, 2020.
    1. Ibrahim M, Jones LJ, Lai NM, et al. . Dexmedetomidine for analgesia and sedation in newborn infants receiving mechanical ventilation. Cochrane Database Syst Rev;118. 10.1002/14651858.CD012361
    1. Barrington K. Dexmedetomidine:new wonder drug or next neonatal disaster? Neonatal Research, 2022. Available: [Accessed 19 Apr 2022].
    1. Kubota T, Fukasawa T, Kitamura E, et al. . Epileptic seizures induced by dexmedetomidine in a neonate. Brain Dev 2013;35:360–2. 10.1016/j.braindev.2012.05.011
    1. Australasian Neonatal Medicines Formulary . Dexmedetomidine: neowborn use only, 2021. Available:
    1. Baserga M, DuPont TL, Ostrander B, et al. . Dexmedetomidine use in infants undergoing cooling due to neonatal encephalopathy (dice trial): a randomized controlled trial: background, aims and study protocol. Front Pain Res 2021;2:770511. 10.3389/fpain.2021.770511

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj